News & Blog

Meet The Community: Kendall Harvey

Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia

2024 rideATAXIA Hometown Twin Cities, MN

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Meet the Community 2: A Closer Look — Alijana Shakya 

2024 Fuzzy Buzzy Recap

Meet the Community 2: A Closer Look – Alex Fielding

Congressional Resolution Passes to Designate September 25 as “National Ataxia Awareness Day”

Papillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia

Meet the Community: Allison Rice

Stealth BioTherapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance and FARA Ireland to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich’s Ataxia

Meet the 2024 FARA Fellows